GlaxoSmithKline has announced that 250 jobs will be saved at its Montrose plant in Scotland, following an investment of £25m. The site was planned to close in 2007, but was given a reprieve after a review to increase its manufacturing capacity.
GSK said production at Montrose would provide back-up for active ingredients in the treatment of asthma, diabetes and heart disease. The announcement came as GSK said was a significant pipeline of new products which last year generated sales of more than £4.5bn.
GSK Montrose vice president and site director Tom Mahon said: "Staff at Montrose have been exemplary both in the way they have handled all the uncertainty for the site in recent times and doing all they could to support GSK.
"Montrose now has a key part to play in the company's global supply network and will receive significant investment to ensure operations are updated to meet the future needs of our business and the pharmaceutical industry."
First Minister Jack McConnell, in the US for Tartan Week celebrations, said: "An investment of £25m shows the company is committed to Scotland for the long-term."